Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

Zacks
2024-11-11

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Addex Therapeutics Ltd. Sponsored ADR (ADXN) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.

Addex Therapeutics Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Addex Therapeutics Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for ADXN's full-year earnings has moved 244.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that ADXN has returned about 74.4% since the start of the calendar year. In comparison, Medical companies have returned an average of 4.7%. As we can see, Addex Therapeutics Ltd. Sponsored ADR is performing better than its sector in the calendar year.

Another Medical stock, which has outperformed the sector so far this year, is Adma Biologics (ADMA). The stock has returned 400.4% year-to-date.

In Adma Biologics' case, the consensus EPS estimate for the current year increased 14.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).

Looking more specifically, Addex Therapeutics Ltd. Sponsored ADR belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have lost about 0.5% so far this year, so ADXN is performing better this group in terms of year-to-date returns.

In contrast, Adma Biologics falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 504 stocks and is ranked #77. Since the beginning of the year, the industry has moved +0.7%.

Going forward, investors interested in Medical stocks should continue to pay close attention to Addex Therapeutics Ltd. Sponsored ADR and Adma Biologics as they could maintain their solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Addex Therapeutics Ltd. Sponsored ADR (ADXN) : Free Stock Analysis Report

ADMA Biologics Inc (ADMA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10